Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer
Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential...
Saved in:
| Published in | Chinese medical journal Vol. 126; no. 23; pp. 4510 - 4516 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
China
Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
05.12.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0366-6999 2542-5641 2542-5641 |
| DOI | 10.3760/cma.j.issn.0366-6999.20122931 |
Cover
| Abstract | Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. |
|---|---|
| AbstractList | Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.BACKGROUNDSensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.METHODSThe levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014).RESULTSAll endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014).It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.CONCLUSIONSIt is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC. The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored. All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014). It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. |
| Author | ZENG Xiao-li ZHANG Shao-yan ZHENG Jun-fang YUAN Hui WANG Yan |
| AuthorAffiliation | Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China |
| AuthorAffiliation_xml | – name: Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China |
| Author_xml | – sequence: 1 givenname: Xiao-li surname: ZENG fullname: ZENG, Xiao-li – sequence: 2 givenname: Shao-yan surname: ZHANG fullname: ZHANG, Shao-yan – sequence: 3 givenname: Jun-fang surname: ZHENG fullname: ZHENG, Jun-fang – sequence: 4 givenname: Hui surname: YUAN fullname: YUAN, Hui – sequence: 5 givenname: Yan surname: WANG fullname: WANG, Yan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24286416$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkc1u1DAURi1URKeFV0BmAWKTwbEdJ1lQqRrxJ1VCQrC27jj2jCPHTu1EZXh6HGamC1awshfnfvruuVfowgevEXpdkjWrBXmnBlj3a5uSXxMmRCHatl1TUlLasvIJWtGK06ISvLxAq0fgEl2l1BNCq6oWz9Al5bTJiFihw62bdNQdHuy3ouQMgz_9K4L1zzHqlGzwCVuPRx3tuNcRHN66EDIXcrlZOQ0RK-1cwiZE3FnY-ZBswsHgDBRpAOf-ANjNfocVeKXjc_TUgEv6xem9Rj8-fvi--Vzcff30ZXN7VyjO6qkoSSUqRpiuRbcVoq0rMA2FxnRABGu6LauampFaKaOb0tBWEEM01Ary4lBTdo1ujrmzH-HwkKvIMdoB4kGWRC5OZXYqe7k4lYsyuSiTZ6c54M0x4AG8Ab-TfZijz5Xlr70a-swxygglGXx7BMcY7medJjnYtKwNXoc5yZILWgvOBc_oyxM6bwfdPTY6HyYD74-AiiGlqM1_l978Na_sBFM-5RTBun9OeXVK2Qe_u7d5-XMN3jBKaVOx3wuhx_k |
| CitedBy_id | crossref_primary_10_3109_1354750X_2016_1153724 crossref_primary_10_3892_etm_2016_3555 crossref_primary_10_18632_oncotarget_21644 crossref_primary_10_1002_jcb_29214 crossref_primary_10_1080_13813455_2020_1752257 crossref_primary_10_3390_genes10030185 crossref_primary_10_1080_07853890_2021_2000634 crossref_primary_10_3390_cancers15194774 crossref_primary_10_3390_ijms150711973 crossref_primary_10_1038_s41598_018_25900_z crossref_primary_10_1371_journal_pone_0134220 crossref_primary_10_1016_j_bbagen_2014_11_023 crossref_primary_10_1111_resp_12444 crossref_primary_10_1186_s12867_015_0052_6 crossref_primary_10_1089_dna_2019_4796 crossref_primary_10_1017_S0007114516001173 crossref_primary_10_1007_s12032_016_0815_z crossref_primary_10_1007_s13277_014_2188_2 crossref_primary_10_1155_2018_5930951 crossref_primary_10_23736_S2784_8477_21_01970_7 crossref_primary_10_3892_ol_2015_3170 crossref_primary_10_1007_s13277_014_2330_1 crossref_primary_10_3390_molecules19068220 crossref_primary_10_1016_j_gene_2015_07_015 crossref_primary_10_1039_C5MB00364D |
| Cites_doi | 10.1186/1476-4598-9-136 10.1155/2011/732690 10.1373/clinchem.2010.157198 10.1093/nar/gni178 10.2174/092986709787581833 10.1158/1078-0432.CCR-09-2638 10.1016/j.cca.2010.02.074 10.1038/sj.onc.1209913 10.1016/j.juro.2008.10.149 10.1038/leu.2011.81 10.1093/carcin/bgr223 10.1210/jc.2008-1451 10.1016/j.bbrc.2009.12.182 10.3816/CLC.2009.n.006 10.1038/nature02871 10.3322/caac.20006 10.1101/gad.1399806 10.1001/jama.297.9.953 10.1016/j.ccr.2006.01.025 10.1159/000113489 10.1159/000218166 10.1016/j.biopha.2010.01.018 10.1016/j.biocel.2009.12.014 10.1200/JCO.2009.24.9342 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 2B. 4A8 92I 93N PSX TCJ ADTOC UNPAY |
| DOI | 10.3760/cma.j.issn.0366-6999.20122931 |
| DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer |
| EISSN | 2542-5641 |
| EndPage | 4516 |
| ExternalDocumentID | 10.3760/cma.j.issn.0366-6999.20122931 zhcmj201323020 24286416 10_3760_cma_j_issn_0366_6999_20122931 48322285 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: This study was supported by grants from the National Natural Science Foundation of China; the Cooperative Research Project of Foundation and Clinic from Capital Medical University funderid: (30900247); (11JL48) |
| GroupedDBID | --- -05 -0E -SE -S~ .55 .GJ 29B 2B. 2C~ 2RA 2WC 3V. 40I 53G 5GY 5RE 5VR 5VS 6J9 7X7 88E 8FI 8FJ 92F 92I 92L 92M 93N 93R 9D9 9DE AAHPQ AASCR ABASU ABCQX ABDIG ABUWG ABVCZ ABXLX ACGFO ACGFS ACILI ADGGA ADHPY ADPDF ADRAZ AENEX AFDTB AFKRA AFUIB AHMBA AHVBC AINUH AJIOK AJNWD ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI ANFDX AOHHW BENPR BPHCQ BVXVI C1A CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CQIGP CW9 DIK DIWNM EBS EEVPB EJD F5P FA0 FCALG FRP FYUFA GNXGY GQDEL GROUPED_DOAJ GX1 HLJTE HMCUK HYE IAO IHR IHW IKREB INH INR IPNFZ ITC JUIAU KQ8 L7B M1P M48 OK1 OPUJH OVD OVDNE OVEED OXXIT P2P P6G PIMPY PQQKQ PROAC PSQYO PV9 Q-- Q-4 R-E RIG RLZ RNS RPM RT5 RZL S.. T8U TCJ TEORI TGQ TR2 TSPGW U1F U1G U5E U5O UKHRP W2D W91 WFFXF X7J X7M XSB ZA5 ZGI ZXP ~WA 0R~ AAAAV AAIQE AAYXX ABZZY ACXJB ADKSD AFBFQ AHQNM AJCLO AJZMW AKCTQ ALKUP AOQMC BQLVK CITATION OVT ALIPV CGR CUY CVF ECM EIF H13 NPM PHGZM PHGZT PJZUB PPXIY 7X8 4A8 PMFND PSX ADTOC PUEGO UNPAY |
| ID | FETCH-LOGICAL-c437t-10565303e76db66975af82a8fda0638db3587307ccfe81f2960f0ea7ca699a723 |
| IEDL.DBID | UNPAY |
| ISSN | 0366-6999 2542-5641 |
| IngestDate | Mon Sep 15 10:19:55 EDT 2025 Thu May 29 03:55:56 EDT 2025 Thu Oct 02 08:06:39 EDT 2025 Mon Jul 21 05:55:47 EDT 2025 Thu Apr 24 23:02:10 EDT 2025 Wed Oct 01 03:41:25 EDT 2025 Wed Feb 14 10:39:00 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 23 |
| Keywords | microRNA diagnosis carcinoma,non-small cell lung |
| Language | English |
| License | cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c437t-10565303e76db66975af82a8fda0638db3587307ccfe81f2960f0ea7ca699a723 |
| Notes | 11-2154/R Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. microRNA;carcinoma,non-small cell lung;diagnosis ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://doi.org/10.3760/cma.j.issn.0366-6999.20122931 |
| PMID | 24286416 |
| PQID | 1462764464 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | unpaywall_primary_10_3760_cma_j_issn_0366_6999_20122931 wanfang_journals_zhcmj201323020 proquest_miscellaneous_1462764464 pubmed_primary_24286416 crossref_primary_10_3760_cma_j_issn_0366_6999_20122931 crossref_citationtrail_10_3760_cma_j_issn_0366_6999_20122931 chongqing_primary_48322285 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-12-05 |
| PublicationDateYYYYMMDD | 2013-12-05 |
| PublicationDate_xml | – month: 12 year: 2013 text: 2013-12-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | China |
| PublicationPlace_xml | – name: China |
| PublicationTitle | Chinese medical journal |
| PublicationTitleAlternate | Chinese Medical Journal |
| PublicationTitle_FL | Chinese Medical Journal |
| PublicationYear | 2013 |
| Publisher | Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China |
| Publisher_xml | – name: Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China |
| References | Ortholan (R19-20-20240102) 2009; 16 Lin (R12-20-20240102) 2011; 25 Takagi (R10-20-20240102) 2009; 77 Yanaihara (R18-20-20240102) 2006; 9 Hu (R25-20-20240102) 2010; 28 Valencia-Sanchez (R4-20-20240102) 2006; 20 Chen (R20-20-20240102) 2005; 33 Wu (R22-20-20240102) 2011; 124 Watanabe (R15-20-20240102) 2011; 25 Wu (R13-20-20240102) 2010; 392 Slaby (R8-20-20240102) 2007; 72 Gao (R28-20-20240102) 2010; 64 McDonald (R23-20-20240102) 2011; 57 Rabinowits (R27-20-20240102) 2009; 10 Lulla (R14-20-20240102) 2011; 2011 Bi (R21-20-20240102) 2011; 124 Zhang (R26-20-20240102) 2010; 411 Lin (R9-20-20240102) 2009; 181 Bach (R3-20-20240102) 2007; 297 Bishop (R24-20-20240102) 2010; 16 Srivastava (R17-20-20240102) 2011; 32 Iio (R11-20-20240102) 2010; 9 Amaral (R16-20-20240102) 2009; 94 Jemal (R1-20-20240102) 2009; 59 Kent (R6-20-20240102) 2006; 25 Cho (R7-20-20240102) 2010; 42 Ambros (R5-20-20240102) 2004; 431 |
| References_xml | – volume: 9 start-page: 136 year: 2010 ident: R11-20-20240102 article-title: Identification of non-coding RNAs embracing microRNA-143145 cluster. publication-title: Mol Cancer doi: 10.1186/1476-4598-9-136 – volume: 124 start-page: 2616 year: 2011 ident: R22-20-20240102 article-title: MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. publication-title: Chin Med J – volume: 2011 start-page: 732690 year: 2011 ident: R14-20-20240102 article-title: Identification of differentially expressed microRNAs in Osteosarcoma. publication-title: Sarcoma doi: 10.1155/2011/732690 – volume: 57 start-page: 833 year: 2011 ident: R23-20-20240102 article-title: Analysis of circulating microRNA: preanalytical and analytical challenges. publication-title: Clin Chem doi: 10.1373/clinchem.2010.157198 – volume: 33 start-page: e179 year: 2005 ident: R20-20-20240102 article-title: Real-time quantification of microRNAs by stem-loop RT-PCR. publication-title: Nucleic Acids Res doi: 10.1093/nar/gni178 – volume: 16 start-page: 1047 year: 2009 ident: R19-20-20240102 article-title: MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. publication-title: Curr Med Chem doi: 10.2174/092986709787581833 – volume: 16 start-page: 610 year: 2010 ident: R24-20-20240102 article-title: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2638 – volume: 411 start-page: 846 year: 2010 ident: R26-20-20240102 article-title: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). publication-title: Clin Chim Acta doi: 10.1016/j.cca.2010.02.074 – volume: 25 start-page: 6188 year: 2006 ident: R6-20-20240102 article-title: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. publication-title: Oncogene doi: 10.1038/sj.onc.1209913 – volume: 181 start-page: 1372 year: 2009 ident: R9-20-20240102 article-title: MicroRNA-143 as a tumor suppressor for bladder cancer. publication-title: J Urol doi: 10.1016/j.juro.2008.10.149 – volume: 25 start-page: 1324 year: 2011 ident: R15-20-20240102 article-title: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. publication-title: Leukemia doi: 10.1038/leu.2011.81 – volume: 32 start-page: 1832 year: 2011 ident: R17-20-20240102 article-title: MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. publication-title: Carcinogenesis doi: 10.1093/carcin/bgr223 – volume: 94 start-page: 320 year: 2009 ident: R16-20-20240102 article-title: MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-1451 – volume: 392 start-page: 340 year: 2010 ident: R13-20-20240102 article-title: MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2009.12.182 – volume: 10 start-page: 42 year: 2009 ident: R27-20-20240102 article-title: Exosomal microRNA: a diagnostic marker for lung cancer. publication-title: Clin Lung Cancer doi: 10.3816/CLC.2009.n.006 – volume: 431 start-page: 350 year: 2004 ident: R5-20-20240102 article-title: The functions of animal microRNAs. publication-title: Nature doi: 10.1038/nature02871 – volume: 59 start-page: 225 year: 2009 ident: R1-20-20240102 article-title: Cancer statistics, 2009. publication-title: CA Cancer J Clin doi: 10.3322/caac.20006 – volume: 20 start-page: 515 year: 2006 ident: R4-20-20240102 article-title: Control of translation and mRNA degradation by miRNAs and siRNAs. publication-title: Genes Dev doi: 10.1101/gad.1399806 – volume: 297 start-page: 953 year: 2007 ident: R3-20-20240102 article-title: Computed tomography screening and lung cancer outcomes. publication-title: JAMA doi: 10.1001/jama.297.9.953 – volume: 9 start-page: 189 year: 2006 ident: R18-20-20240102 article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.01.025 – volume: 72 start-page: 397 year: 2007 ident: R8-20-20240102 article-title: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. publication-title: Oncology doi: 10.1159/000113489 – volume: 77 start-page: 12 year: 2009 ident: R10-20-20240102 article-title: Decreased expression of microRNA-143 and -145 in human gastric cancers. publication-title: Oncology doi: 10.1159/000218166 – volume: 64 start-page: 399 year: 2010 ident: R28-20-20240102 article-title: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2010.01.018 – volume: 25 start-page: 739 year: 2011 ident: R12-20-20240102 article-title: MicroRNA expression profiles in human colorectal cancers with liver metastases. publication-title: Oncol Rep – volume: 42 start-page: 1273 year: 2010 ident: R7-20-20240102 article-title: MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2009.12.014 – volume: 124 start-page: 3164 year: 2011 ident: R21-20-20240102 article-title: miRNA deregulation in multiple myeloma. publication-title: Chin Med J – volume: 28 start-page: 721 year: 2010 ident: R25-20-20240102 article-title: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-smallcell lung cancer. publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.9342 |
| SSID | ssj0025576 |
| Score | 2.1788034 |
| Snippet | Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic... Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and... Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic... |
| SourceID | unpaywall wanfang proquest pubmed crossref chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4510 |
| SubjectTerms | Aged Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Female Gene Expression Regulation, Neoplastic Humans Leukocytes, Mononuclear - metabolism Male MicroRNAs - genetics Middle Aged miRNA 外周血单个核细胞 外周血单核细胞 小分子RNA 生物标志物 诊断 非小细胞肺癌 鳞状细胞癌 |
| Title | Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer |
| URI | http://lib.cqvip.com/qk/85656X/201323/48322285.html https://www.ncbi.nlm.nih.gov/pubmed/24286416 https://www.proquest.com/docview/1462764464 https://d.wanfangdata.com.cn/periodical/zhcmj201323020 https://doi.org/10.3760/cma.j.issn.0366-6999.20122931 |
| UnpaywallVersion | publishedVersion |
| Volume | 126 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2542-5641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025576 issn: 2542-5641 databaseCode: KQ8 dateStart: 20000101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2542-5641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025576 issn: 2542-5641 databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2542-5641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025576 issn: 2542-5641 databaseCode: GX1 dateStart: 20000101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVOVD databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling customDbUrl: eissn: 2542-5641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025576 issn: 2542-5641 databaseCode: OVEED dateStart: 20060101 isFulltext: true titleUrlDefault: http://ovidsp.ovid.com/ providerName: Ovid |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VW6niwvuRAsVIcMySOH6kEpcVolRIrRBi0XKyHNtpt-xmy2ZX0P56ZvJYFbi0XKIcnIk8_jzzTWYyBnjFc1-KtHC4kXwSCy_S2OZpGScena3b1z5rimiOjtXhWHycyMkWyP5fmCv5eyrXeOPmdnjW7Ich2loVKyQ0VJDF0U1h0LOtJFLwAWyPjz-NvrV5yXYQHSonBQZaSqQ78Ppa8qi_wumiOvmBXuNPP_UP-cSh6-rcXvy0s1nzv09V2urkims6uANf-0m1FSnfh-tVMXSXf_V7vPGs78LtjqyyUYuue7AVqvuwc9Sl4x_AxYhy7cGz-fRzjJSI2aq7lwkLv7oa26pm04pRR-WmhcGMNcXyDPG_qKibsl0ySh_UDPkz823p37Rmi5LhgLie49ybAWyGhok5gunyIYwP3n95dxh3ZznETmR6hdYemSO6y6CVL5Ta19KWObd56S2RJl9kMkdjo50rA2KF46qWSbDaWZy71Tx7BAN8aXgCjCung5P0AaYUHvlRmvigM15wn8iQhAh2N6toztueHUaQ5eK5jOBtv6zGdV3Q6TCOmcFoiHRvUPcYEZHuDenekO5Nr_sI1ObxXvQ1H3zZY8jgBiat2Sos1jXFXlwjK1UigsctuDaikT_liF8Vgd6g7abvfdFh03TGqTaXp25-xinJlmGwsPvfsp_CLZLSFPfIZzBYLdfhOVK0VbHXfNrA64dJutdtzt8VWC-S |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VW6niwvuR8jISHLMkjh-pxGWFqCqkVgixqJwsx3baLdls2ewK2l_PTB6rApeWWw7ORB5_nvkmMx4DvOa5L0VaONxIPomFF2ls87SME4_O1u1pn7VFNIdH6mAqPh7L4y2Qw1mYK_l7Ktd46-Z2fNbuhzHaWhUrJDRUkMXRTWHQs60kUvARbE-PPk2-dXnJbhBdKicFBlpKpDvw5lryqL_C6aI--YFe408_9Q_5xKHr-txe_LRV1Z73qUtbn1xxTft34Oswqa4i5ft4vSrG7vKvfo83nvVduN2TVTbp0HUPtkJ9H3YO-3T8A7iYUK49eDaffY6REjFb988yYeFXX2NbN2xWM-qo3LYwqFhbLM8Q_4uauinbJaP0QcOQPzPflf7NGrYoGQ6ImznOvR3AKjRMzBFMlw9huv_hy_uDuL_LIXYi0yu09sgc0V0GrXyh1J6Wtsy5zUtviTT5IpM5GhvtXBkQKxxXtUyC1c7i3K3m2SMY4UfDE2BcOR2cpB8wpfDIj9LEB53xgvtEhiREsLtZRXPe9ewwgiwXz2UE74ZlNa7vgk6XcVQGoyHSvUHdY0REujeke0O6N4PuI1Cb1wfR13zx1YAhgxuYtGbrsFg3FHtxjaxUiQged-DaiEb-lCN-VQR6g7abfvdlj03TG6fGXJ66-RmnJFuGwcLuf8t-CrdISlvcI5_BaLVch-dI0VbFi35D_gbrjC2s |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Altered+miR-143+and+miR-150+expressions+in+peripheral+blood+mononuclear+cells+for+diagnosis+of+non-small+cell+lung+cancer&rft.jtitle=%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=ZENG+Xiao-li+ZHANG+Shao-yan+ZHENG+Jun-fang+YUAN+Hui+WANG+Yan&rft.date=2013-12-05&rft.issn=0366-6999&rft.eissn=2542-5641&rft.issue=23&rft.spage=4510&rft.epage=4516&rft_id=info:doi/10.3760%2Fcma.j.issn.0366-6999.20122931&rft.externalDocID=48322285 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85656X%2F85656X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhcmj%2Fzhcmj.jpg |